[A comparison of the hypolipidemic action of probucol at doses of 500 and 1000 mg/day in moderate hyperlipoproteinemia].
OBJECTIVE
Evaluation of effectiveness of hypolipidemic action of probucol in doses 500 and 1000 mg/day and comparison of probucol blood concentrations on the treatment month 3 and 6.


METHODS
Probucol (Akrikhin, Russia) was given to 41 patients with primary hypercholesterolemia in a dose 500 mg/day. 3 months later the patients were divided into two groups. Group 1 patients exhibited a > 10% decrease in cholesterol levels and continued to take probucol in the dose 500 mg/day. Group 2 patients were crossed over to higher cholesterol dose--up to 1000 mg/day. Lipids levels were measured by enzyme tests, apoproteins--by immunoturbidimetry and immunodiffusion, probucol concentrations--by high-performance liquid chromatography.


RESULTS
After 3 months of treatment, cholesterol lowered by 14.3 and 9.2% in groups 1 and 2, respectively. After 6 months, by 19.7 and 12.9%, respectively. Probucol concentrations in blood were higher after 6 months of treatment than after 3 months in both groups. No significant differences existed between the groups by probucol concentrations in 3 and 6 months.


CONCLUSIONS
Hypolipidemic effect of probucol depended on the individual features of lipoproteins metabolic disorders rather than the drug blood concentration. Larger probucol doses fail to reduce cholesterol further.
M G
MG
Tvorogova
V P
VP
Lupanov
E Iu
EIu
Nuraliev
T M
TM
Zaĭtseva
V V
VV
Kukharchuk
V N
VN
Titov
D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood; D003131:Combined Modality Therapy; D018752:Diet, Fat-Restricted; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011341:Probucol / Q000008:administration & dosage* / Q000097:blood; D013997:Time Factors
D001053:Apolipoproteins; D000960:Hypolipidemic Agents; D008055:Lipids; D011341:Probucol
Sopostavlenie gipolipidemicheskogo deĭstviia probukola v doze 500 i 1000 mg/sut pri umerennoĭ giperlipoproteidemii.